Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Eden Research plc (EDL)

  Print      Mail a friend

Monday 28 June, 2010

Eden Research plc

Option Agreement with Certis Europe BV for nema...

                                                                                                 22 June 2010

                                           EDEN RESEARCH PLC
                                         ("Eden" or "Company")

                         Option Agreement with Certis Europe BV for nematodes

Eden Research plc, a leading UK agrochemical development company, today announces that it has signed an exclusive
option  agreement  for  its  nematicide product and technology with Certis  Europe  BV  ("Certis")  based  in
Maarssen, Netherlands. The agreement gives Certis a period of twelve months exclusivity within which it  will
conduct various investigations on the performance and economics of the product and technology following which
it  can  exercise its option and  enter into an exclusive licence agreement for the use of Eden's  nematicide
product in major markets in Europe, Asia, Africa, the Middle East and Oceania.

The agreement provides for Certis to pay an upfront fee of $100,000 followed by a license fee on exercise of the
option of $900,000, plus an annual royalty payment once sales have begun.

Eden's  nematicide product is based upon two of the terpenes contained in its 3-AEY Botrytis product that  is
already  well  advanced  in  its EU registration process. Terpenes are natural compounds  which  function  as
defence  mechanisms in many plant groups and are released in response to infection, attack by pests (in  this
case  soil-inhabiting nematodes), stress or mechanical injury. Terpenes are already widely used in  the  food
flavouring, cosmetic and pharmaceutical industries.

Certis Europe BV is a well established crop protection business with direct operations in key European markets
which combines proprietary products with those from a range of supplier partners in a wide-ranging portfolio.
Certis'  majority  shareholder  is Mitsui Agriscience, part of Mitsui & Co., a  $57  billion  global  trading
company with diverse business interests in over 90 countries. Mitsui's global sales in the agriscience sector
are  in  excess  of  $486  million  per  annum and the company markets  a  wide  variety  of  pesticides  and
biopesticides,  as  well  as  biological pest control products and services through  its  European,  African,
Japanese and US subsidiaries.

Clive Newitt, Managing Director of Eden Research, said:

"This is a significant step forward for Eden as the worldwide nematicide and soil fumigant market is around $1
billion  per  annum  and,  therefore, provides us with the potential for  significant  future  revenues.  Our
nematicide is the next significant product in our portfolio to be commercialised and this agreement is a very
good  start  in  licensing the product on a worldwide basis. It leaves us only the North American  and  South
American regions to be out-licensed in the future. The worldwide nematode market is currently crying out  for
new  products with advantageous safety profiles, such as ours, to replace those products which are  being  or
have already been banned or restricted in use."

Kevin Price, corporate marketing manager  of Certis Europe,  said:

"Certis Europe is continuously working on further strengthening of our CleanStart offer to the
market. CleanStart comprises a range of various soil treatment products and solutions for prevention
and control of pests and diseases. We are continuously looking for effective, safe and innovative
solutions with a good safety profile for man and environment that can complement our current product
range that includes the soil disinfectants Basamid and DD. This terpenes based technology for nematode
control is looking very promising to meet those requirements and we are happy to be able to review it
more in detail during the coming year".


Eden Research plc                                                                01993 862761
Clive Newitt, Managing Director

Certis Europe BV
Kevin Price, corporate marketing manager                                         +44 7900 276 216

St Helens Capital Partners LLP                                                   020 7368 6959
Mark Anwyl

Eden Research plc

a d v e r t i s e m e n t